Enlivex receives Nasdaq delisting notice over bid price
Enlivex (NASDAQ:ENLV) received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement. The company, which completed a reverse share split, plans to appeal. Enlivex is developing Allocetra, an immunotherapy for age-related inflammatory conditions.
How this was made
The 30-second read
Why it matters
The delisting notice introduces significant downside risk, but the appeal process may provide temporary trading continuity. Investors should monitor Nasdaq hearing outcomes and any subsequent compliance actions.
Market read
The news is highly relevant for ENLV shareholders and traders focused on micro‑cap biotech stocks, with immediate price pressure expected.
What to watch
Potential hidden cash from the prediction‑markets treasury strategy and any upcoming clinical data could mitigate the delisting risk.
Background
Enlivex Ltd. (NASDAQ:ENLV) received a Nasdaq delisting notice after failing to maintain the $1 minimum bid price for 30 consecutive business days. The company cannot use a 180‑day compliance period due to a recent 1‑for‑16 reverse split and has filed an appeal.
Ticker impact
Nasdaq issued a delisting notice to Enlivex after its shares failed to meet the $1 bid price for 30 days and it cannot use a compliance period due to a recent reverse split.
likely pressure as the market prices in the delisting risk and potential loss of Nasdaq listing
A delisting notice is a material corporate action that typically triggers sell‑offs, especially for a micro‑cap with limited liquidity.
Market effects
Minimal impact on the broader biotech sector; the issue is company‑specific.
Limited to U.S. small‑cap and Nasdaq‑listed biotech investors.
Low global relevance; primarily affects ENLV shareholders.
Counterpoint
If ENLV successfully appeals, the stock could rebound sharply on relief rally.
Key entities
- CompanyEnlivex Ltd.
Developer of the Allocetra immunotherapy platform.
- Regulatory BodyNasdaq
Issuer of the delisting notice under Listing Rule 5815.
